TGA approval for Abbott's new FreeStyle Libre 2

Latest News

Abbott has announced that its next-generation, sensor-based glucose monitoring technology, FreeStyle Libre 2, is now registered for use in Australia.

The registration is for adults and children (4 and older) with insulin-dependent diabetes. The company said the device will be made available in Australia over the coming months and be priced the same as the current FreeStyle Libre system.

The company said features of the FreeStyle Libre 2 include high 14-day accuracy, excellent performance, trends, insights and actionable data with the mobile app10 or on a reader, in a fully disposable device.

Its new features include automated, optional, real-time alarms and the ability to measure glucose levels every minute. These features give users the option to be alerted in real-time of critical events such as hypoglycemia or hyperglycemia.

The wearable technology, which eliminates the need for painful fingersticks, also provides people living with diabetes with actionable information to better manage their condition.

Abbott said it will now work with the Department of Health to advance the process of including the FreeStyle Libre 2 system on the National Diabetes Services Scheme.

"Abbott’s next-generation FreeStyle Libre 2 offers an important choice, with its breakthrough technology and the same price as the popular FreeStyle Libre system," said Peter Chalikias, regional director of Abbott’s diabetes care business in Australia and New Zealand. "This latest technology is designed to simplify a condition that is not without challenges, and is also accessible to as many people living with diabetes as possible in Australia."